Managing the transition: switching bioanalytical laboratories during a clinical trial - a sponsor's perspective.

Bioanalytical (BA) data are foundational to clinical trial integrity and regulatory success. Yet, circumstances such as regulatory noncompliance, operational disruptions, resource limitations, or evolving analytical needs can necessitate a BA laboratory transition during a clinical trial. Through the lens of a real-world case study and supported by broader industry experience, this manuscript explores the operational, scientific, and regulatory challenges of BA laboratory transitions. We examine four potential scenarios that trigger such changes, the risks to data continuity and compliance, and the significant implications for sponsors. The manuscript outlines actionable, multidisciplinary strategies for managing transitions: from vendor qualification and project planning to Corrective and Preventive Action (CAPA) implementation, method transfer, and ongoing performance assessment. When guided by early risk recognition, transparent communication, and organizational learning, laboratory transitions though challenging, can be successfully navigated to protect trial outcomes and strengthen the resilience of clinical programs.